Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diadexus, Inc.  stock logo
DDXS
Diadexus
$0.00
$0.01
$5.40
$53KN/A15,481 shs30 shs
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
$30.86
+1.2%
$31.82
$23.72
$37.57
N/AN/A133,004 shs93,235 shs
Merck KGaA stock logo
MKGAY
Merck KGaA
$38.36
$38.36
$32.53
$42.02
N/AN/A6,872 shsN/A
TNGN
Tengion
$0.00
$0.00
$0.00
N/AN/A6,051 shs10,000 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diadexus, Inc.  stock logo
DDXS
Diadexus
0.00%0.00%0.00%0.00%0.00%
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
+0.69%+4.63%-4.63%+5.03%-14.73%
Merck KGaA stock logo
MKGAY
Merck KGaA
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/AN/AN/AN/AN/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/AN/AN/AN/AN/AN/AN/AN/A
Merck KGaA stock logo
MKGAY
Merck KGaA
N/AN/AN/AN/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
1.50
ReduceN/AN/A
Merck KGaA stock logo
MKGAY
Merck KGaA
3.00
BuyN/AN/A
TNGN
Tengion
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/AN/AN/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/AN/AN/AN/AN/AN/A
Merck KGaA stock logo
MKGAY
Merck KGaA
N/AN/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/A$114.690.27N/AN/AN/AN/AN/A
Merck KGaA stock logo
MKGAY
Merck KGaA
N/AN/A0.00N/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/AN/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
$22.4772.81%N/A19.59%N/A
Merck KGaA stock logo
MKGAY
Merck KGaA
N/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
0.05%
Merck KGaA stock logo
MKGAY
Merck KGaA
N/A
TNGN
Tengion
N/A

Insider Ownership

CompanyInsider Ownership
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/A
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
N/A
Merck KGaA stock logo
MKGAY
Merck KGaA
N/A
TNGN
Tengion
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/A4.10 millionN/ANot Optionable
Daiichi Sankyo Company, Limited stock logo
DSNKY
Daiichi Sankyo
17,435N/AN/ANot Optionable
Merck KGaA stock logo
MKGAY
Merck KGaA
N/AN/AN/ANot Optionable
TNGN
Tengion
147,000N/AN/ANot Optionable

MKGAY, DDXS, TNGN, and DSNKY Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Diadexus logo

Diadexus

OTCMKTS:DDXS
Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.
Daiichi Sankyo logo

Daiichi Sankyo

OTCMKTS:DSNKY
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
Merck KGaA logo

Merck KGaA

OTCMKTS:MKGAY
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Tengion

OTCMKTS:TNGN
Tengion, Inc. is a medicine company, focuses on discovering, developing, manufacturing and commercializing of neo-organs and products. The company was founded by Steven Nichtberger and David I. Scheer on July 10, 2003 and is headquartered in Winston-Salem, NC.